Table 1.
First author | Type of study | Overall patient number | Year of publication | Patients number by arm | Chemotherapy regimen | Dose (mg/m²) | Treatment schedule | Treatment duration |
---|---|---|---|---|---|---|---|---|
Carraro [12] | Phase II | 11 | 2001 | 11 | Cisp + Gem | 30 + 1000 | d1d8d15/d1d8d15-q4w | NA |
Malik [13] | Phase II | 11 | 2003 | 11 | Cisp + Gem | 70 + 1000 | d1/d1d8-q3w | Until DP or UT |
Baluch [14] | Phase II | 14 | 2003 | 14 | Cisp + Gem | 60 + 1000 | d1/d1d8-q3w | NA |
Reyes-Vidal [15] | Phase II | 44 | 2003 | 44 | Cisp + Gem | 35 + 1250 | d1d8/d1d8-q3w | NA |
Doval [16] | Phase II | 30 | 2004 | 30 | Cisp + Gem | 70 + 1000 | d1/d1d8-q3w | Six cycles unless DP or UT |
Thongprasert [17] | Phase II | 43 | 2005 | 43 | Cisp + Gem | 75 + 1250 | d1/d1d8-q3w | Until DP or UT |
Kim [18] | Phase II | 29 | 2006 | 29 | Cisp + Gem | 60 + 1250 | d1/d1d8-q3w | Until DP |
Giuliani [19] | Phase II | 38 | 2006 | 38 | Cisp + Gem | 80 + 1000 | d1/d1d8-q3w | Six cycles unless DP or UT |
Park [20] | Phase II | 27 | 2006 | 27 | Cisp + Gem | 75 + 1000 | d1/d1d8d15-q4w | NA |
Lee [21] | Phase II | 24 | 2006 | 24 | Cisp + Gem | 70 + 1000 | d1/d1d8-q3w | Until DP or UT |
Meyerhardt [22] | Phase II | 33 | 2007 | 33 | Cisp + Gem | 30 + 1000 | d1d8/d1d8-q3w | Until DP or UT |
Charoentum [23] | Retrospective study | 42 | 2007 | 42 | Cisp + Gem | 75 + 1250 | d1/d1d8-q3w | NA |
Lee [21] | Phase II | 35 | 2008 | 35 | Cisp + Gem | 70 + 1250 | d1/d1d8-q3w | Eight cycles |
Valle [24] | Randomized comparative Phase II | 86 | 2009 | 42 | Cisp + Gem | 25 + 1000 | d1d8/d1d8-q3w | Eight cycles unless DP or UT |
44 | Gem | 1000 | d1d8d15-q4w | Six cycles unless DP or UT | ||||
Goldstein [25] | Phase II | 50 | 2010 | 50 | Cisp + Gem | 20 + 1000 | d1d8/d1d8-q3w | Until DP or UT |
Okusaka [26] | Randomized comparative Phase II | 83 | 2010 | 41 | Cisp + Gem | 25 + 1000 | d1d8/d1d8-q3w | Sixteen cycles unless DP or UT |
42 | Gem | 1000 | d1d8d15-q4w | Twelve cycles unless DP or UT | ||||
Valle [8] | Phase III | 410 | 2010 | 204 | Cisp + Gem | 25 + 1000 | d1d8/d1d8-q3w | Eight cycles unless DP or UT |
206 | Gem | 1000 | d1d8d15-q3w | Six cycles unless DP or UT | ||||
Weatherly [27] | Retrospective study | 85 | 2011 | 53 | Cisp + Gem | NA | NA | NA |
32 | “Alternative” regimens | NA | NA | NA |
DP, disease progression; UT, unacceptable toxicity.